Sarepta Therapeutics Inc


Market Cap$12.61B

Compare Sarepta Therapeutics

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Sarepta Therapeutics IncSarepta Therapeutics Inc-18.20%-62%9.81.4
marketMarket Avg49.61.28%30%6.11.1
HealthcareHealthcare Avg32.71.25%19%7.40.9

Current Fair Value

28% upside

Undervalued by 28% based on the discounted cash flow analysis.

Share Statistics

Market cap$12.61 Billion
Enterprise Value$12.17 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-7.81
Outstanding Shares93,546,681
Avg 30 Day Volume917,110


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-18.25
Price to Sales9.84
Price to Book Ratio14.21
Enterprise Value to Revenue9.79
Enterprise Value to EBIT-45.44
Enterprise Value to Net Income-23
Total Debt to Enterprise0.1
Debt to Equity1.44

Revenue Sources

No data

ESG Score

No data

About Sarepta Therapeutics Inc

CEO: Douglas Ingram

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...